Compare KRUS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | GERN |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 753.3M |
| IPO Year | 2019 | 1996 |
| Metric | KRUS | GERN |
|---|---|---|
| Price | $54.37 | $1.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $84.29 | $3.00 |
| AVG Volume (30 Days) | 304.1K | ★ 6.8M |
| Earning Date | 01-07-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,763,000.00 | $183,403,000.00 |
| Revenue This Year | $18.91 | $147.42 |
| Revenue Next Year | $20.16 | $39.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.88 | ★ 522.13 |
| 52 Week Low | $40.03 | $1.04 |
| 52 Week High | $106.60 | $3.68 |
| Indicator | KRUS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 53.73 |
| Support Level | $50.73 | $1.30 |
| Resistance Level | $56.62 | $1.37 |
| Average True Range (ATR) | 2.41 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 65.70 | 23.33 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.